Sirnaomics Ltd. (HK:2257)
:2257
Want to see HK:2257 full AI Analyst Report?
2257 Stock Chart & Stats
HK$8.00
-HK$0.09(-2.79%)
At close: 4:00 PM EST
HK$8.00
-HK$0.09(-2.79%)
Day’s Range― - ―
52-Week RangeHK$3.00 - HK$22.78
Previous CloseN/A
Volume36.40K
Average Volume (3M)442.62K
Market Cap
HK$639.68M
Enterprise ValueHK$76.86M
Total Cash (Recent Filing)HK$13.52M
Total Debt (Recent Filing)HK$9.31M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding109,721,535
10 Day Avg. Volume408,789
30 Day Avg. Volume442,620
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-9.39
Price to Sales (P/S)0.00
P/FCF Ratio-10.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$162.00M
Bulls Say, Bears Say
Bulls Say
Narrowing Net LossThe material narrowing of net loss in 2025 versus prior years suggests improving cost structure or program discipline. Sustained reduction in losses over several quarters can extend runway and reduce near-term financing pressure, supporting continued R&D execution.
Improved Cash BurnMeaningful improvement in cash burn across 2024–2025 indicates better operating efficiency and slower depletion of resources. If sustained, this improvement lengthens the company’s runway, giving management time to advance clinical programs before needing external capital.
Specialized RNAi PlatformA clear strategic focus on siRNA therapeutics and delivery technologies is a durable competitive asset. Delivery is a high barrier area in RNAi; deep technical expertise and a focused pipeline in oncology can create long-term differentiation and potential partner interest.
Bears Say
Zero/volatile RevenueRevenue absence and volatility mean the business is not generating predictable commercial cash flow. This undermines self-sufficiency, forces reliance on external funding for R&D, increases dilution risk, and limits ability to invest steadily in programs long-term.
Negative Shareholder EquityTransition to negative shareholder equity signals a weakened capital base and reduces financial flexibility. Negative equity complicates borrowing, heightens refinancing risk, and typically presages increased equity issuance or restructuring that can impair long-term investor returns.
Persistent Cash Flow DeficitChronic negative operating and free cash flow demonstrates the company is not self-financing its R&D. Continued deficits necessitate repeated external financing, which can dilute shareholders, distract management, and constrain sustained investment in high-cost clinical development.
Sirnaomics Ltd. News
2257 FAQ
What was Sirnaomics Ltd.’s price range in the past 12 months?
Sirnaomics Ltd. lowest stock price was HK$3.00 and its highest was HK$22.78 in the past 12 months.
What is Sirnaomics Ltd.’s market cap?
Sirnaomics Ltd.’s market cap is HK$639.68M.
When is Sirnaomics Ltd.’s upcoming earnings report date?
Sirnaomics Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 98 days.
How were Sirnaomics Ltd.’s earnings last quarter?
Sirnaomics Ltd. released its earnings results on Mar 27, 2026. The company reported -HK$0.881 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.881.
Is Sirnaomics Ltd. overvalued?
According to Wall Street analysts Sirnaomics Ltd.’s price is currently Overvalued.
Does Sirnaomics Ltd. pay dividends?
Sirnaomics Ltd. does not currently pay dividends.
What is Sirnaomics Ltd.’s EPS estimate?
Sirnaomics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sirnaomics Ltd. have?
Sirnaomics Ltd. has 109,721,535 shares outstanding.
What happened to Sirnaomics Ltd.’s price movement after its last earnings report?
Sirnaomics Ltd. reported an EPS of -HK$0.881 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.516%.
Which hedge fund is a major shareholder of Sirnaomics Ltd.?
Currently, no hedge funds are holding shares in HK:2257
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sirnaomics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
207.69%
12-Months-Change
Fundamentals
Return on Equity
191.92%
Trailing 12-Months
Asset Growth
-27.12%
Trailing 12-Months
Company Description
Sirnaomics Ltd.
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Clover Biopharmaceuticals Ltd.
―
CStone Pharmaceuticals
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―